BCL2 and neoplasm: By contrast, the combination of sirolimus with inhibitors of the anti-apoptotic proteins BCL2 (venetoclax) and MCL1 (S63845) was both well tolerated by normal tissues and highly active in inducing apoptosis in tumor cells (Figs. 6, 7, and S15).